OCUL Ocular Therapeutix RESULTS: Q2, Q2 product REV $13.48M, Q2 EPS $-0.35
OCUL Ocular Therapeutix RESULTS: Q2, Q2 product REV $13.48M, Q2 EPS $-0.35
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.